New drug combo tested for rare blood cancer
NCT ID NCT07233720
Summary
This study is observing how well a combination of two drugs, zanubrutinib and rituximab, works as the first treatment for people with marginal zone lymphoma, a type of blood cancer. It will follow 30 patients who have not had any prior cancer treatment to see how many achieve a complete response and to monitor side effects. The goal is to gather real-world data on the effectiveness and safety of this treatment approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.